bazedoxifene has been researched along with Triple Negative Breast Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Guo, K; Lin, J | 1 |
| Fu, S; Lin, J | 1 |
| Cao, Y; Chen, X; Fu, S; Lin, HJ; Lin, J; Lo, HW; Pan, L; Tian, J; Wu, X; Xiao, H; Zhang, R; Zhang, Y | 1 |
3 other study(ies) available for bazedoxifene and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Letter to the editor regarding the article "Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer".
Topics: Cytokine Receptor gp130; Humans; Indoles; Interleukin-6; Triple Negative Breast Neoplasms | 2021 |
Blocking Interleukin-6 and Interleukin-8 Signaling Inhibits Cell Viability, Colony-forming Activity, and Cell Migration in Human Triple-negative Breast Cancer and Pancreatic Cancer Cells.
Topics: Benzamides; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclobutanes; Drug Synergism; Female; Humans; Indoles; Interleukin-6; Interleukin-8; Neoplastic Stem Cells; Pancreatic Neoplasms; Signal Transduction; Sulfonamides; Triple Negative Breast Neoplasms | 2018 |
Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cytokine Receptor gp130; Down-Regulation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Interleukin-6; Mice; Paclitaxel; Phosphorylation; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2019 |